Immunotherapy

Papers
(The H4-Index of Immunotherapy is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors167
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings70
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens66
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait61
A global picture: therapeutic perspectives for COVID-1953
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis35
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma34
Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?34
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report31
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins28
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)27
Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis26
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma26
Interferons: role in cancer therapy26
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia24
Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma24
Immunotherapy for gastric cancer: a 2021 update24
Systemic immune–inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis24
The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy23
Tumor cell-based vaccine: an effective strategy for eradication of cancer cells22
Therapeutics to tackle Omicron outbreak22
Antimicrobial/anticancer peptides: bioactive molecules and therapeutic agents22
TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases22
0.024029016494751